



Zolgensma[®] (onasemnogene abeparvovec-xioi) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for Precertification Review)

Aetna Precertification Notification

Phone: 1-866-752-7021

FAX: 1-888-267-3277

For Medicare Advantage Part B:

Phone: 1-866-503-0857

FAX: 1-844-268-7263

Please indicate: Start of treatment: Start date ____ / ____ / ____
 Continuation of therapy, Date of last treatment ____ / ____ / ____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:	DOB:
Address:	City:	State: ZIP:
Home Phone:	Work Phone:	Cell Phone: Email:
Patient Current Weight: _____ lbs or _____ kgs	Patient Height: _____ inches or _____ cms	Allergies:

B. INSURANCE INFORMATION

Aetna Member ID #: _____	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #: _____	If yes, provide ID#: _____ Carrier Name: _____
Insured:	Insured:
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #:	Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #:

C. PRESCRIBER INFORMATION

First Name:	Last Name:	(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.
Address:	City:	State: ZIP:
Phone:	Fax:	St Lic #: NPI #: DEA #: UPIN:
Provider Email:	Office Contact Name:	Phone:
Specialty (Check one): <input type="checkbox"/> Neurologist <input type="checkbox"/> Pediatrician <input type="checkbox"/> Other: _____		

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration: <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____ Address: _____	Dispensing Provider/Pharmacy: Patient Selected choice <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Other _____ Name: _____ Address: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____
---	---

E. PRODUCT INFORMATION

Request is for: Zolgensma (onasemnogene abeparvovec-xioi)
Dose: _____ Frequency: _____

F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (Clinical documentation must be submitted with request):

Yes No Has the patient received Zolgensma (onasemnogene abeparvovec-xioi) in the past?

Yes No Does the patient have a genetically confirmed diagnosis of spinal muscular atrophy (SMA)?

Yes No Is there documentation of bi-allelic mutations in the survival motor neuron 1 (SMN1) gene?

Yes No Please select: SMN1 deletions SMN1 point mutations

 Please enter the date genetic testing was completed: Date: ____ / ____ / ____

Yes No Is the patient's anti-adenovirus 9 (AAV9) antibody titer less than or equal to 1:50 as determined by enzyme-linked immunosorbent assay (ELISA) binding immunoassay?

Yes No Does the patient have any of the following indicators of advanced disease?

The patient does not have advanced disease

 Please select: Complete paralysis of limbs Invasive ventilatory support (tracheostomy) Respiratory assistance for 16 or more hours per day (including non-invasive respiratory support) continuously for 14 or more days in the absence of acute reversible illness (excluding perioperative ventilation)

Other indicators of advanced disease-Please explain: _____

Yes No Is the medication prescribed by or in consultation with a physician who specializes in treatment of SMA?

Yes No Is the patient currently receiving therapy with Spinraza (nusinersen) or Evrysdi (risdiplam)? Date of last dose: ____ / ____ / ____

Yes No Will Spinraza (nusinersen) or Evrysdi (risdiplam) be discontinued prior to administration of Zolgensma (onasemnogeneabeparvovec-xioi)?

Continued on next page



Zolgensma (onasemnogene abeparvovec-xioi) Medication

Precertification Request

Page 2 of 2

All fields must be completed and legible for Precertification Review)

Aetna Precertification Notification

Phone: 1-866-752-7021

FAX: 1-888-267-3277

For Medicare Advantage Part B:

Phone: 1-866-503-0857

FAX: 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.

Please provide the name of the gene therapy designated center Zolgensma (onasemnogene abeparvovec-xioi) will be administered at:

Name: _____

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.